Mechanism of Action

Ghrelin Receptor Agonist

ENTYCE® (capromorelin oral solution) is a ghrelin receptor agonist that mimics the effect of ghrelin (the “hunger hormone”). Like naturally occurring ghrelin, ENTYCE binds to specific cell receptors and affects signaling in the hypothalamus, causing the feeling of hunger.

Several studies demonstrating efficacy and safety in laboratory and client-owned dogs treated with ENTYCE have been conducted.1,2

Multivesicular liposomes
1.Zollers B, Huebner M, Armintrout G, Rausch-Derra LC, Rhodes L. Evaluation of the safety in dogs of long-term, daily oral administration of capromorelin (ENTYCE®), a novel drug for stimulation of appetite. J Vet Pharmacol Ther. 2016 Sep 25. doi: 10.1111/jvp.12358.
2.Zollers B, Wofford JA, Heinen E, Huebner M, Rhodes L. A Prospective, Randomized, Masked, Placebo-Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite. J Vet Intern Med. 2016; 30(6):1851-1857.

Clinical References

Your convenient one-stop source for viewing and downloading important information.

Learn more >

In-Clinic Tools

Introducing ENTYCE to your clinic as a therapeutic solution specifically designed to stimulate appetite in dogs.

Learn more >

News

Keep current on all the latest Aratana news, upcoming conferences and other timely information.

Learn more >

IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.

ENTYCE is Now Available

Other therapeutics from Aratana

Nocita Logo

NOCITA® (bupivacaine liposome injectable suspension)

provides post-operative pain relief for cranial cruciate ligament surgery for up to 72 hours.

Now you can be sure dogs are getting the post-surgical pain relief they need even after they leave your clinic.

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.